OrganonOGN +0.22%73 EBITDA Margin % is 28.08% as of Mar. 2026, which is 6% below its 10-year median of 29.94. GuruFocus rates OGN with a GF Score™ of 73/100 and a GF Value™ of $14.55 (Fairly Valued). The stock has 9 warning signs investors should review. Among 955 Drug Manufacturers companies, Organon ranks better than 74.35% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Organon's EBITDA for the
three
months ended in Mar. 2026 was $410 Mil. Organon's Revenue for the
three
months ended in Mar. 2026 was $1,460 Mil. Therefore, Organon's EBITDA margin for the quarter that ended in Mar. 2026 was 28.08%.
Organon (NYSE:OGN) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Organon EBITDA Margin % Related Terms
Organon EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Organon's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OGN vs AMRN, SCLX, MIRA: EBITDA Margin % Comparison
For the Drug Manufacturers - General subindustry, Organon's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organon EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Organon's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Organon's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organon (OGN) has a EBITDA Margin % of 28.08% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Organon and its competitors. This is near median its historical median of 29.94. Over the past decade, Organon's EBITDA Margin % has ranged from 20.75 to 51.81. According to the industry distribution chart, Organon ranks #245 out of 955 companies in the Drug Manufacturers industry, placing it in the top 25.7%.
Is Organon's EBITDA Margin % too high?
Organon's current EBITDA Margin % of 28.08% is near median its 10-year median of 29.94. Over the past 10 years, this metric has ranged from a low of 20.75 to a high of 51.81. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Organon's value of 28.08% is 126.6% above this industry median. Based on the distribution chart, Organon ranks #245 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Organon has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Organon's EBITDA Margin % compare to AMRN and SCLX?
According to the Drug Manufacturers industry distribution chart, Organon ranks #245 out of 955 companies for EBITDA Margin %. This puts Organon in the upper half of its industry. The industry median EBITDA Margin % is 12.39. Organon's value of 28.08% is 126.6% above this benchmark. Historically, Organon's own EBITDA Margin % has ranged from 20.75 to 51.81 over the past decade. While the company's 10-year median is 29.94 vs. the industry median of 12.39, Organon has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Organon's current EBITDA Margin % of 28.08% is 126.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Organon and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organon's current EBITDA Margin % is 28.08%, which is near median its own 10-year median of 29.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organon stock overvalued right now?
Based on GuruFocus' analysis, Organon (OGN) is currently considered Fairly Valued. The stock's GF Value™ is $14.55, compared to a current price of $13.48 — trading 7.4% below its estimated fair value. The current EBITDA Margin % is 28.08%, which is near median its 10-year median of 29.94 and 126.6% above the Drug Manufacturers industry median of 12.39. Organon's overall GF Score™ is 73/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Organon (OGN), the current EBITDA Margin % is 28.08% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organon (OGN) Overvalued in 2026?
Based on GuruFocus' analysis, Organon stock appears to be undervalued.
The current stock price of $13.48 is trading 7.4% below its estimated GF Value™ of $14.55.
GuruFocus considers Organon to be Fairly Valued.
Key valuation signals for OGN:
EBITDA Margin %: 28.08% (near median its 10-year median of 29.94)
GF Value™: $14.55 vs. price of $13.48 (7.4% below fair value)
Industry Position: 126.6% above the Drug Manufacturers median (#245 of 955)
No single metric tells the full story. See the OGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
73GF Score
Get the complete analysis for OGN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OGN has been successfully added to your 
